{
    "2020-04-20": [
        [
            {
                "time": "2023-10-01",
                "original_text": "Alexion Will Test Rare Disease Drug in Covid-19 Patients",
                "features": {
                    "keywords": [
                        "Alexion",
                        "Rare Disease Drug",
                        "Covid-19",
                        "Patients"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Moderna, Sanofi, Vaxart and Eli Lilly",
                "features": {
                    "keywords": [
                        "Zacks Analyst Blog",
                        "Regeneron Pharmaceuticals",
                        "Moderna",
                        "Sanofi",
                        "Vaxart",
                        "Eli Lilly"
                    ],
                    "sentiment_score": 0.65,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "5 Top Must-Buy Stocks Set to Beat on Q1 Earnings This Week",
                "features": {
                    "keywords": [
                        "Top Must-Buy Stocks",
                        "Q1 Earnings"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "general market"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "RPT-Drug trial specialists see coronavirus-fueled spike in demand for virtual services",
                "features": {
                    "keywords": [
                        "Drug trial specialists",
                        "coronavirus",
                        "demand",
                        "virtual services"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "technology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}